| ID Source | ID |
|---|---|
| PubMed CID | 3136666 |
| CHEMBL ID | 235890 |
| CHEBI ID | 125151 |
| SCHEMBL ID | 4351836 |
| Synonym |
|---|
| EU-0014533 |
| TIMTEC1_004043 |
| thiadiazole derivative, 13 |
| bdbm23998 |
| 5''-(4-methylphenyl)-1,2-dihydro-3''h-spiro[indole-3,2''-[1,3,4]thiadiazole]-2-one |
| CHEBI:125151 |
| HMS1545H17 |
| CHEMBL235890 |
| SCHEMBL4351836 |
| 5'-(4-methylphenyl)spiro[1h-indole-3,2'-3h-1,3,4-thiadiazole]-2-one |
| BRD-A41649729-001-01-0 |
| AKOS024269833 |
| Q27215495 |
| 5'-(4-methylphenyl)-2-spiro[1h-indole-3,2'-3h-1,3,4-thiadiazole]one |
| Class | Description |
|---|---|
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) | IC50 (µMol) | 3.7000 | 0.5000 | 4.4750 | 10.0000 | AID1798388; AID301383 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) |
| extracellular space | A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) |
| endoplasmic reticulum lumen | A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) |
| collagen-containing extracellular matrix | A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) |
| extracellular matrix | A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1798388 | ADAMTS-5 Inhibition Assay from Article 10.1016/j.bmcl.2007.07.048: \\5'-Phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one inhibitors of ADAMTS-5 (aggrecanase-2).\\ | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20 | 5'-Phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one inhibitors of ADAMTS-5 (aggrecanase-2). |
| AID301383 | Inhibition of ADAMTS5 by FRET assay | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20 | 5'-Phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one inhibitors of ADAMTS-5 (aggrecanase-2). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||